SG11202109997PA - Novel azaindole derivative - Google Patents

Novel azaindole derivative

Info

Publication number
SG11202109997PA
SG11202109997PA SG11202109997PA SG11202109997PA SG 11202109997P A SG11202109997P A SG 11202109997PA SG 11202109997P A SG11202109997P A SG 11202109997PA SG 11202109997P A SG11202109997P A SG 11202109997PA
Authority
SG
Singapore
Prior art keywords
azaindole derivative
novel azaindole
novel
derivative
azaindole
Prior art date
Application number
Inventor
Gen Watanabe
Toshiharu Morimoto
Akira Iwata
Hirotaka Sasaki
Takahisa Ogamino
Kosuke Usuda
Ayumu Okuda
Hiroyuki Ishiwata
Yuichiro Tabunoki
Keigo Nishii
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of SG11202109997PA publication Critical patent/SG11202109997PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202109997P 2019-03-29 2020-03-30 Novel azaindole derivative SG11202109997PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019068233 2019-03-29
PCT/JP2020/014475 WO2020203950A1 (en) 2019-03-29 2020-03-30 Novel azaindole derivative

Publications (1)

Publication Number Publication Date
SG11202109997PA true SG11202109997PA (en) 2021-10-28

Family

ID=72668977

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109997P SG11202109997PA (en) 2019-03-29 2020-03-30 Novel azaindole derivative

Country Status (10)

Country Link
US (1) US20220162206A1 (en)
EP (1) EP3950063A4 (en)
JP (1) JPWO2020203950A1 (en)
KR (1) KR20210146320A (en)
CN (1) CN113613729A (en)
BR (1) BR112021019050A2 (en)
CA (1) CA3134937A1 (en)
MX (1) MX2021011923A (en)
SG (1) SG11202109997PA (en)
WO (1) WO2020203950A1 (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288918A (en) * 1992-09-29 1994-02-22 Union Carbide Chemicals & Plastics Technology Corporation Hydroformylation process
US5767321A (en) * 1995-12-06 1998-06-16 Union Carbide Chemicals & Plastics Technology Corporation Metal-ligand complex catalyzed processes
PT1696920E (en) * 2003-12-19 2015-01-14 Plexxikon Inc Compounds and methods for development of ret modulators
JP2008503473A (en) 2004-06-17 2008-02-07 プレキシコン，インコーポレーテッド Compounds that modulate C-KIT activity
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US20110262425A1 (en) 2007-12-12 2011-10-27 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
KR101656548B1 (en) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 Antibodies against human csf-1r and uses thereof
US9358235B2 (en) * 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
CA2960574C (en) * 2014-10-23 2023-03-07 Janssen Pharmaceutica Nv Pyrazolopyrimidine derivatives as nik inhibitors
AU2016297558B2 (en) * 2015-07-20 2021-03-25 Genzyme Corporation Colony stimulating factor-1 receptor (CSF-1R) inhibitors
US20200071326A1 (en) * 2017-04-14 2020-03-05 Syros Pharmaceuticals, Inc. Tam kinase inhibitors

Also Published As

Publication number Publication date
US20220162206A1 (en) 2022-05-26
KR20210146320A (en) 2021-12-03
JPWO2020203950A1 (en) 2020-10-08
EP3950063A1 (en) 2022-02-09
CA3134937A1 (en) 2020-10-08
MX2021011923A (en) 2021-11-03
BR112021019050A2 (en) 2021-11-30
WO2020203950A1 (en) 2020-10-08
EP3950063A4 (en) 2022-11-30
CN113613729A (en) 2021-11-05

Similar Documents

Publication Publication Date Title
IL286846A (en) Camptothecin derivatives
IL275365A (en) 6-azaindole compounds
GB202201999D0 (en) Interleukin-2 Derivative
ZA202204675B (en) New methylquinazolinone derivatives
IL289197A (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
IL290964A (en) 2-aminoquinazolinone derivative
IL289589A (en) Novel methods
EP3406612A4 (en) Carboline derivative serving as bromodomain inhibitor
IL279938A (en) Spirochromane derivatives
IL290815A (en) Alpha-d-galactopyranoside derivatives
SI3796975T1 (en) Sulfonylaminobenzamide derivatives
IL288950A (en) Pyridin-3-yl derivatives
SG11202007979UA (en) Dihydrochromene derivative
EP3885347A4 (en) Dihydropyrrolopyrazole derivative
SG11202006837XA (en) Dihydroindolizinone derivative
SG11202109997PA (en) Novel azaindole derivative
GB201919210D0 (en) Dihydro-cyclopenta-isoquinoline derivatives
GB201911764D0 (en) Novel Methods
GB201911762D0 (en) Novel methods
GB201919213D0 (en) Dihydrocyclopenta-Isoquinoline-Sulfanamide derivatives compounds
EP3872061A4 (en) 1-phenyl-2-phenylethane derivative
EP4062972A4 (en) Pyrazolomorphinan derivative
GB201917413D0 (en) Zeolite
GB201901043D0 (en) Novel methods
GB201914325D0 (en) Novel meethod